Why Penny Stock VYNE Therapeutics (VYNE) Is Skyrocketing Today - VYNE Therapeutics (NASDAQ:VYNE)

VYNE Therapeutics Inc VYNE announced that the first vitiligo patient had been dosed in a Phase 1a/b trial of VYN201, a locally administered, small molecule, pan-bromodomain and extra-terminal domain (BET) inhibitor for immuno-inflammatory diseases.
The clinical trial is a first-in-human study designed to generate safety and pharmacokinetic data in healthy volunteers (Phase 1a) and provide early clinical proof-of-concept data in vitiligo patients (Phase 1b).
The company expects topline data for Phase 1a and Phase 1b parts of the study in the first half of 2023.
In the Phase 1b portion, up to 30 patients with a clinical diagnosis of non-segmental vitiligo will receive VYN201 once daily in up to three dose cohorts.
The primary objective of the Phase 1b portion of the study will be to evaluate the safety and pharmacokinetics of VYN201.
The exploratory efficacy of VYN201 in non-segmental vitiligo patients will also be evaluated, including pharmacodynamic biomarkers and photography.
In August, VYNE Therapeutics announced results from the Phase 2a segment of a Phase 1b/2 trial of FMX114 for mild-to-moderate atopic dermatitis (AD), missing the primary endpoint of the disease severity index.
Price Action: VYNE shares are up 56.6% at $0.30 on the last check Tuesday.

Why Penny Stock VYNE Therapeutics Is Skyrocketing Today?